Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimasertib plus SAR245409 versus pimasertib plus placebo in previously treated unresectable low-grade ovarian cancer
2013-000902-40Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC), low-grade serous ovarian carcinoma (LGSOC) and 1 more comparing Pimasertib + SAR245409 with Pimasertib + placebo (2 arms). Primary endpoint: Objective tumor response. Started Nov 2013; status: completed.
02
Drugs
pimasertibvoxtalisib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)low-grade serous ovarian carcinoma (LGSOC)serous peritoneal carcinoma (PPSC)
Beyond the preview
Go deeper on 2013-000902-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000902-40.